Antabio SAS advances cystic fibrosis programme

Antabio said it will use the second tranche of a 2017 CARB-X grant to complete non-GLP studies on
the company‘s Pseudomonas Elastase inhibitor (PEi) programme, which is believed to improve efficacy of current symptomatic cystic fibrosis therapy.

The small molecule candidate reduced the severity of P. aeruginosa disease and enhanced pathogen clearance in vivo by targeting the LasB elastase, a key virulence factor that contributes to tissue damage and inflammation in infected lungs of patients with cystic fibrosis.

The majority (>80%) of adult Cystic Fibrosis (CF) patients has acute and chronic infections caused by P. aeruginosa, which resist immune clearance and conventional antibiotics, leading to treatment failure, chronic infection and recurrent acute exacerbations. P. aeruginosa is one of the most priority pathogens of the World Health Organization (WHO).

„CARB-X funds the best science and most promising research projects around the world to address drug resistance, stated Erin Duffy, CARB-X‘s Chief of R&D. „CARB-X‘s pipeline, which includes Antabio‘s novel PEi approach to AMR, continues to expand with innovative antibiotics and prevention approaches.
About ANTABIO

Besides its PEi programe, Antabio has two beta-lactamase blockers in clinical development.
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of antimicrobial resistanc. CARB-X is led by Boston University and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services , the Wellcome Trust, Germany‘s Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Care‘s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). A non-profit partnership, CARB-X is investing up to $500 million from 2016-2021 to support innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics that address drug-resistant bacteria.